{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-topical-skin-nose-eyes/background-information/action-of-local-corticosteroids/","result":{"pageContext":{"chapter":{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids","depth":2,"htmlHeader":"<!-- begin field 3c011516-c4f4-4ed7-be80-3337ff617a20 --><h2>How do local corticosteroids work?</h2><!-- end field 3c011516-c4f4-4ed7-be80-3337ff617a20 -->","summary":"","htmlStringContent":"<!-- begin item 5bf821cb-80dd-4b63-a7cc-b675084c9ec4 --><!-- begin field 75b4dfde-0923-406a-ba50-5a1b31df96c1 --><ul><li>Local corticosteroids are predominantly glucocorticoids. They have four main effects:<ul><li><strong>Anti-inflammatory </strong>— they inhibit inflammation by blocking the action of inflammatory mediators (such as prostaglandins).</li><li><strong>Immunosuppressive </strong>— they suppress delayed hypersensitivity reactions (by directly affecting T-lymphocytes).</li><li><strong>Anti-proliferative (anti-mitotic) </strong>— they inhibit epidermal DNA synthesis and epidermal cell turnover.</li><li><strong>Vasoconstrictive </strong>— they inhibit the action of histamine and other vasoactive mediators, and also directly affect vascular endothelial cells. The most potent topical steroids are also the most vasoconstrictive.</li></ul></li><li><strong>Topical corticosteroids </strong>exert these effects on the skin to treat various inflammatory skin conditions, such as:<ul><li>Eczema — the anti-inflammatory effects of the corticosteroid are important. In addition, the immunosuppressive effects are of benefit in the treatment of contact dermatitis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/\">Eczema - atopic</a> and <a class=\"topic-reference external-reference\" href=\"/topics/dermatitis-contact/\">Dermatitis - contact</a>.</li><li>Psoriasis — is characterized by rapid cell turnover, and the anti-mitotic effects of corticosteroids are of benefit. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/psoriasis/\">Psoriasis</a>.</li></ul></li><li><strong>Intranasal corticosteroids </strong>exert these effects on the nasal mucosa, where they relieve or prevent the symptoms associated with allergic rhinitis. They can also be used short term to shrink nasal polyps. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/allergic-rhinitis/\">Allergic rhinitis</a>.</li><li><strong>Corticosteroid eye preparations </strong>exert these effects within the eyes, where they control inflammation due to allergy, trauma, or infection.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Coulson, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>]</p><!-- end field 75b4dfde-0923-406a-ba50-5a1b31df96c1 --><!-- end item 5bf821cb-80dd-4b63-a7cc-b675084c9ec4 -->","topic":{"id":"091d926b-472d-55aa-b732-215f8299eb6e","topicId":"fe2967bf-dc0e-4dd2-903c-812a35c0d510","topicName":"Corticosteroids - topical (skin), nose, and eyes","slug":"corticosteroids-topical-skin-nose-eyes","lastRevised":"Last revised in September 2020","chapters":[{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"30c29984-be54-5cc7-b45b-ccea8330c500","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes"},{"id":"110d5d5e-8e14-51d5-ab15-5afa0d551cf7","slug":"update","fullItemName":"Update"}]},{"id":"6481ae53-8731-5bbf-84bb-f9c18452558f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"746ed409-c3cc-5d5f-a043-6c7e517b0f61","slug":"goals","fullItemName":"Goals"},{"id":"40ab5ace-33b8-5a2c-a6bb-cbd7fe8ca07c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc1a105d-dd83-5e54-b930-588a3dbdb5cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f6a0228b-0765-5b1b-b1b7-25eca749a1ab","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"842d280b-d84c-5903-bbdb-3f4fe26412fc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"17589721-7493-5da3-8828-e2b4bec649b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e28586d8-7d65-5f08-a10b-d2d25b975112","slug":"definition","fullItemName":"Definition"},{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids"},{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability"}]},{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment"},{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment"},{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment"}]},{"id":"ebd50a03-95ac-50a9-8a2d-4d615c9569bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0620ec75-3526-5198-b134-4f31d225ab30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2b03e883-8770-59d5-9965-04ffada0e471","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73e06218-1739-5de2-908f-ba65ba970168","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f813f700-2fb0-5989-90bd-2c2aa6dbb85a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3aa0e05-0446-53c0-9de1-2a8d2a9d1a70","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2a6ead30-5d09-5a96-b6d4-b673b755b98a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e78ffc84-8544-5685-8a35-65c8f05aac92","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}